- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
- Interventions
- Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
- Other · Procedure · Drug + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,094
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Gallium 68 Macro-aggregated albumin
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- positron emission tomography/computed tomography, PET/MRI, Position Device
- Diagnostic Test · Device
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage IV Prostate Adenocarcinoma
- Interventions
- Computed Tomography, Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Laboratory Biomarker Analysis, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- Andrei Iagaru
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 25 Years
- Enrollment
- 5,951 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2032
- U.S. locations
- 203
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
- Conditions
- Healthy Controls
- Interventions
- PET imaging
- Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Healthy
- Interventions
- [18F] Flutemetamol
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
- Interventions
- Carboplatin, Computed Tomography, Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium, Oxaliplatin, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Radiation Therapy, Therapeutic Conventional Surgery
- Drug · Procedure · Other + 2 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Rochester, Minnesota
- Conditions
- Multiple Myeloma, Disease of the Marrow, Osteoporosis
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer
- Interventions
- Cisplatin, Carboplatin, Etoposide, Pembrolizumab, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Radiation Therapy
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7
- Interventions
- Computed Tomography, Iodine I 124, Iodine I-131, Laboratory Biomarker Analysis, Pharmacodynamic Study, Positron Emission Tomography, Trametinib
- Procedure · Other · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- 68Ga-PSMA
- Drug
- Lead sponsor
- Ebrahim Delpassand
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Central Nervous System Cancer, Brain Metastases
- Interventions
- [C-11]-CS1P1, Brain MRI
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Lung Cancer
- Interventions
- computed tomography, positron emission tomography
- Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Dallas, Texas • Madison, Wisconsin
- Conditions
- Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- pazopanib hydrochloride, laboratory biomarker analysis, positron emission tomography, computed tomography, fludeoxyglucose F 18
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
- Conditions
- Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Lymphoblastic Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Lymphoblastic Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
- Interventions
- Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Multigated Acquisition Scan, Pheresis, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Tiragolumab, X-Ray Imaging
- Biological · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Carcinosarcoma, Recurrent Female Reproductive System Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinosarcoma, Refractory Fallopian Tube Carcinoma, Refractory Female Reproductive System Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
- Interventions
- Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography
- Biological · Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Brain Stem Glioma, Ependymoblastoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Grade III Meningioma, Meningeal Hemangiopericytoma, Mixed Glioma, Pineal Gland Astrocytoma, Brain Tumor
- Interventions
- therapeutic allogeneic lymphocytes, aldesleukin, laboratory biomarker analysis, positron emission tomography
- Biological · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Recurrent Glioblastoma
- Interventions
- FMISO PET, MRI, Bevacizumab, CCNU
- Device · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California